PMID- 19944317
OWN - NLM
STAT- MEDLINE
DCOM- 20110216
LR  - 20181201
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 54
IP  - 3
DP  - 2009 Dec
TI  - Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in 
      patients with acute myocardial infarction.
PG  - 416-24
LID - 10.1016/j.jjcc.2009.07.001 [doi]
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) plays an important role in 
      the pathogenesis of acute coronary syndrome. We have recently demonstrated that 
      the administration of edaravone before reperfusion attenuated reperfusion injury 
      in patients with acute myocardial infarction (AMI). METHODS: Plasma MCP-1 levels 
      were measured in 45 consecutive patients with AMI (edaravone group, n=25; control 
      group, n=20). In the edaravone group, 30 mg edaravone was intravenously infused 
      just before reperfusion. Plasma samples were obtained before and at 24h, 3, 5, 7, 
      and 14 days after reperfusion. Cardiovascular events were defined as cardiac 
      death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring 
      rehospitalization was evaluated at 12 months after reperfusion. RESULTS: Plasma 
      MCP-1 levels were not different between the two groups before reperfusion. 
      Compared with the placebo group, the edaravone group had statistically lower 
      maximum creatine kinase-MB levels (218+/-31 IU/l versus 145+/-21 IU/l, p<0.05) and 
      plasma MCP-1 levels on day 3 after reperfusion (873+/-118 pg/ml versus 516+/-66 
      pg/ml, p<0.05). Heart failure requiring rehospitalization occurred in four 
      patients in the control group, but did not occur in the edaravone group (p<0.05). 
      At 12 months after reperfusion, left ventricular ejection fraction was 
      statistically higher in the edaravone group than in the control group (62+/-2% 
      versus 54+/-3%, p<0.05). CONCLUSION: Edaravone suppressed plasma MCP-1, improved 
      left ventricular ejection fraction, and reduced rehospitalization due to heart 
      failure. Suppression of plasma MCP-1 level by edaravone might induce better 
      prognosis for AMI patients.
FAU - Nakamura, Yoshinori
AU  - Nakamura Y
AD  - Fukuoka Tokushukai Medical Center, 4-5 Sukukita, Kasuga, Fukuoka 816-0864, Japan. 
      nakamurayoshi2004@yahoo.co.jp
FAU - Yamada, Yoshihiro
AU  - Yamada Y
FAU - Shimomura, Hideki
AU  - Shimomura H
FAU - Nagayoshi, Yasuhiro
AU  - Nagayoshi Y
FAU - Tsujita, Kenichi
AU  - Tsujita K
FAU - Yamashita, Takuro
AU  - Yamashita T
FAU - Fukuda, Masaya
AU  - Fukuda M
FAU - Ohba, Keisuke
AU  - Ohba K
FAU - Nako, Hisato
AU  - Nako H
FAU - Ogura, Yuji
AU  - Ogura Y
FAU - Chitose, Tadasuke
AU  - Chitose T
FAU - Yamaguchi, Munetaka
AU  - Yamaguchi M
FAU - Nagata, Takeshi
AU  - Nagata T
FAU - Soejima, Hirofumi
AU  - Soejima H
FAU - Kaikita, Koichi
AU  - Kaikita K
FAU - Sugiyama, Seigo
AU  - Sugiyama S
FAU - Ogawa, Hisao
AU  - Ogawa H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090820
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Free Radical Scavengers)
RN  - S798V6YJRP (Edaravone)
RN  - T3CHA1B51H (Antipyrine)
SB  - IM
MH  - Aged
MH  - Angioplasty, Balloon, Coronary
MH  - Antipyrine/administration & dosage/*analogs & derivatives
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood/physiology
MH  - Edaravone
MH  - Female
MH  - Free Radical Scavengers/*administration & dosage
MH  - Heart Failure/prevention & control
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/etiology/physiopathology/*therapy
MH  - Myocardial Reperfusion Injury/*prevention & control
MH  - Patient Readmission/statistics & numerical data
MH  - Prognosis
MH  - Stroke Volume
MH  - Ventricular Function, Left
EDAT- 2009/12/01 06:00
MHDA- 2011/02/17 06:00
CRDT- 2009/12/01 06:00
PHST- 2009/01/05 00:00 [received]
PHST- 2009/06/21 00:00 [revised]
PHST- 2009/07/07 00:00 [accepted]
PHST- 2009/12/01 06:00 [entrez]
PHST- 2009/12/01 06:00 [pubmed]
PHST- 2011/02/17 06:00 [medline]
AID - S0914-5087(09)00215-9 [pii]
AID - 10.1016/j.jjcc.2009.07.001 [doi]
PST - ppublish
SO  - J Cardiol. 2009 Dec;54(3):416-24. doi: 10.1016/j.jjcc.2009.07.001. Epub 2009 Aug 
      20.